Older adults with chronic obstructive pulmonary disease (COPD) found the Wellinks health mobile app useful and valuable for managing the disease and treatment, a small pilot study suggests. According to study authors, the Wellinks platform may aid patient engagement and outcomes. “It’s exciting to see this population of chronically ill patients successfully…
A pilot study on the first wireless nebulizer for use by people with chronic obstructive pulmonary disease (COPD) has been cleared by a review board of the U.S. Food and Drug Administration (FDA), Wellinks, the nebulizer’s developer, announced. “Getting into the field with our first digital health offering…
The clinical stage biopharmaceutical Pulmatrix, recently announced the completion of a pilot study to access the pharmacokinetics of PUR0200 for maintenance treatment of bronchospasms in patients with chronic obstructive pulmonary disease (COPD). The testing of PUR0200, a dry powdered generic of a once-daily, long-acting muscarinic antagonist, was done using healthy volunteers. In Europe,…
Get regular updates to your inbox.